These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 25231401)

  • 21. Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines.
    Ayyagari VN; Hsieh TJ; Diaz-Sylvester PL; Brard L
    BMC Cancer; 2017 Jan; 17(1):49. PubMed ID: 28086831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells.
    Arisan ED; Kutuk O; Tezil T; Bodur C; Telci D; Basaga H
    Breast Cancer Res Treat; 2010 Jan; 119(2):271-81. PubMed ID: 19238538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
    Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
    Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Role of apoptosis-associated genes and caspase-3 in cisplatin-resistant human ovarian cancer cell lines].
    Yang XK; Xing H; Zheng F; Gao QL; Wang W; Lu YP; Ma D
    Zhonghua Fu Chan Ke Za Zhi; 2003 Mar; 38(3):158-61. PubMed ID: 12816691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of lipoplatin in tumor and in normal cells in vitro.
    Arienti C; Tesei A; Ravaioli A; Ratta M; Carloni S; Mangianti S; Ulivi P; Nicoletti S; Amadori D; Zoli W
    Anticancer Drugs; 2008 Nov; 19(10):983-90. PubMed ID: 18827563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
    Henkels KM; Turchi JJ
    Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
    Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Personalized Medicine-Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids.
    Raghavan S; Mehta P; Ward MR; Bregenzer ME; Fleck EMA; Tan L; McLean K; Buckanovich RJ; Mehta G
    Clin Cancer Res; 2017 Nov; 23(22):6934-6945. PubMed ID: 28814433
    [No Abstract]   [Full Text] [Related]  

  • 29. ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signature.
    Roy L; Samyesudhas SJ; Carrasco M; Li J; Joseph S; Dahl R; Cowden Dahl KD
    Oncotarget; 2014 Sep; 5(18):8355-66. PubMed ID: 25327563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
    Puvanenthiran S; Essapen S; Seddon AM; Modjtahedi H
    Int J Oncol; 2016 Nov; 49(5):1825-1838. PubMed ID: 27599579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effects of compound Daqiqi decoction combined cisplatin on Bcl-2/Bax expression of nude mice ovarian cancer subcutaneous transplanted tumor].
    Yang YB; Wang S; Li S; Chen R
    Zhongguo Zhong Yao Za Zhi; 2015 Apr; 40(8):1575-9. PubMed ID: 26281601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liposomal cisplatin: a new cisplatin formulation.
    Stathopoulos GP
    Anticancer Drugs; 2010 Sep; 21(8):732-6. PubMed ID: 20671511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.
    Ai Z; Lu Y; Qiu S; Fan Z
    Cancer Lett; 2016 Apr; 373(1):36-44. PubMed ID: 26801746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hsp70 promotes chemoresistance by blocking Bax mitochondrial translocation in ovarian cancer cells.
    Yang X; Wang J; Zhou Y; Wang Y; Wang S; Zhang W
    Cancer Lett; 2012 Aug; 321(2):137-43. PubMed ID: 22281241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model.
    Chan JK; Pham H; You XJ; Cloven NG; Burger RA; Rose GS; Van Nostrand K; Korc M; Disaia PJ; Fan H
    Cancer Res; 2005 Apr; 65(8):3243-8. PubMed ID: 15833856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TIMP3 regulates osteosarcoma cell migration, invasion, and chemotherapeutic resistances.
    Han XG; Li Y; Mo HM; Li K; Lin D; Zhao CQ; Zhao J; Tang TT
    Tumour Biol; 2016 Jul; 37(7):8857-67. PubMed ID: 26749283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The alkaloid emetine sensitizes ovarian carcinoma cells to cisplatin through downregulation of bcl-xL.
    Sun Q; Yogosawa S; Iizumi Y; Sakai T; Sowa Y
    Int J Oncol; 2015 Jan; 46(1):389-94. PubMed ID: 25310746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanistic Nanotherapeutic Approach Based on siRNA-Mediated DJ-1 Protein Suppression for Platinum-Resistant Ovarian Cancer.
    Schumann C; Chan S; Khalimonchuk O; Khal S; Moskal V; Shah V; Alani AW; Taratula O; Taratula O
    Mol Pharm; 2016 Jun; 13(6):2070-83. PubMed ID: 27170529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The potent peptide antagonist to angiogenesis, C16Y, and cisplatin act synergistically in the down-regulation of the Bcl-2/Bax ratio and the induction of apoptosis in human ovarian cancer cells.
    Shinagawa A; Yoshida Y; Kurokawa T; Horiuchi Y; Tsuyoshi H; Orisaka M; Sawamura Y; Kleinman HK; Kotsuji F
    Int J Oncol; 2011 Dec; 39(6):1359-64. PubMed ID: 21935568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.